Corrigendum to “Role of integrated cancer nanomedicine in overcoming drug resistance” [Adv. Drug Deliv. Rev. 65 (2013) 1784–1802]
Advanced Drug Delivery Reviews · 2026-07 · 234 · 115860
DOI: 10.1016/j.addr.2026.115860 ↗Kurz gefasst
Korrektur in der Zeitschrift Advanced Drug Delivery Reviews, 2026-07. Verfasst von Arun K Iyer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, USA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, USA.
- Nemucore Medical Innovations, Inc., Worcester, MA 01608, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, USA. Electronic address: m.amiji@neu.edu.
Zitieren
APA
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2026). Corrigendum to “Role of integrated cancer nanomedicine in overcoming drug resistance” [Adv. Drug Deliv. Rev. 65 (2013) 1784–1802]. Advanced Drug Delivery Reviews, 234, 115860. https://doi.org/10.1016/j.addr.2026.115860
Vancouver
Iyer AK, Singh A, Ganta S, Amiji MM. Corrigendum to “Role of integrated cancer nanomedicine in overcoming drug resistance” [Adv. Drug Deliv. Rev. 65 (2013) 1784–1802]. Advanced Drug Delivery Reviews. 2026;234:115860. doi:10.1016/j.addr.2026.115860
BibTeX
@article{Iyer2026,
author = {Iyer, Arun K and Singh, Amit and Ganta, Srinivas and Amiji, Mansoor M},
title = {Corrigendum to “Role of integrated cancer nanomedicine in overcoming drug resistance” [Adv. Drug Deliv. Rev. 65 (2013) 1784–1802]},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {234},
pages = {115860},
doi = {10.1016/j.addr.2026.115860}
}
EUVIMED